title: First case of septicemia due to a strain belonging to enteric group 58 (Enterobacteriaceae) and its designation as Averyella dalhousiensis gen. nov., sp. nov., based on analysis of strains from 20 additional cases.
abstract: When enteric group 58 was first described as a distinct new group of Enterobacteriaceae in 1985, there were only five known human isolates: four from wounds and one from feces. In 1996, we investigated the first blood isolate of enteric group 58, a case of sepsis in a 33-year-old woman receiving total parenteral nutrition. Fifteen additional clinical isolates have since been identified at CDC, including several recognized from a collection of "unidentified" strains dating back to 1973. All strains were characterized with a standard set of 49 biochemical tests used for Enterobacteriaceae, and the results were analyzed to determine phenotypic relatedness and best taxonomic fit. Antibiograms were determined as a taxonomic tool. Original identifications provided by submitting laboratories encompassed a wide variety of Enterobacteriaceae, including 14 species in eight genera, the most common being Enterobacter spp., Salmonella spp., Serratia spp., Kluyvera spp., or Escherichia spp. Enteric group 58 strains have been most frequently isolated from traumatic injuries, fractures, and wounds and rarely from feces. Defining its clinical significance and distinguishing infection from colonization requires further study, but our case report indicates that serious systemic infection can occur. The vernacular name enteric group 58 was used from 1985 to 2004. In this paper, we formally name it Averyella dalhousiensis gen. nov., sp. nov., on the basis of its unique phenotype and its unique 16S rRNA gene sequence. These data indicate that enteric group 58 is not closely related to any of the existing genera or species of Enterobacteriaceae. The type strain is designated CDC 9501--97, and a phenotypic definition is given based on all 21 strains.
authors.affiliation: Department of Medicine and Pathology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada. asjohnson_@hotmail.com
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Johnson
authors.forename: Cheryl L
authors.initials: CL
authors.lastname: Tarr
authors.forename: B H
authors.initials: BH
authors.lastname: Brown
authors.forename: Karen M
authors.initials: KM
authors.lastname: Birkhead
authors.forename: J J
authors.initials: JJ
authors.lastname: Farmer
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000382:microbiology*; D015373:Bacterial Typing Techniques; D004269:DNA, Bacterial / Q000032:analysis; D004275:DNA, Ribosomal / Q000032:analysis; D004755:Enterobacteriaceae / Q000145:classification* / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D004756:Enterobacteriaceae Infections / Q000382:microbiology; D005260:Female; D020459:Genes, rRNA; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010641:Phenotype; D010802:Phylogeny; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D017422:Sequence Analysis, DNA
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S